{
    "clinical_study": {
        "@rank": "125971", 
        "arm_group": [
            {
                "arm_group_label": "Testosterone", 
                "arm_group_type": "Active Comparator", 
                "description": "Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators' hypotheses are: Low-dose testosterone augmentation improves depressive\n      symptoms in women with Major Depressive Disorder (MDD) and antidepressant\n      partial/nonresponse, adjunctive low-dose testosterone is safe and well-tolerated in women\n      with MDD and antidepressant partial/nonresponse, and low-dose testosterone augmentation\n      improves fatigue and sexual dysfunction."
        }, 
        "brief_title": "Testosterone Antidepressant Augmentation in Women", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Depression", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Female, age 21-75\n\n          2. Major depressive disorder including MADRS>/=12\n\n          3. Currently treated with an antidepressant monotherapy (1st, 2nd or 3rd trial in\n             current episode), that has been taken at an adequate dose for at least six weeks.\n\n        Exclusion Criteria:\n\n          1. Serious suicide or homicide risk, as assessed by evaluating clinician\n\n          2. Unstable medical illness including cardiovascular, hepatic, renal, respiratory,\n             endocrine, neurologic\n\n          3. Substance use disorder active within last six months, or clinical suspicion of\n             ongoing substance use disorder at the discretion of the study clinician at time of\n             screening based on history and/or laboratory results.\n\n          4. Any history of psychotic features, bipolar disorder, or primary obsessive compulsive\n             disorder, as assessed by SCID\n\n          5. Currently treated with typical or atypical antipsychotic medications, or lithium\n\n          6. Untreated hypothyroidism. If treated hypothyroidism, change in levothyroxine dose\n             within the prior 3 mos\n\n          7. Use of androgens, including testosterone, dehydroepiandrosterone (DHEA) and\n             methyltestosterone, within the prior three months\n\n          8. Any investigational psychotropic drug within the last thirty days\n\n          9. In the judgment of the study clinician, unlikely to be able to participate safely\n             throughout the study period (three or more episodes of self-harm in the past year,\n             documented history of poor treatment adherence, or frequent missed appointments\n             (>50%) in the past year)\n\n         10. ALT > 3x upper limit of normal or creatinine> 3x upper limit\n\n         11. History of a hormone-responsive cancer"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783574", 
            "org_study_id": "2012D000537", 
            "secondary_id": "R34MH09931501A1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Testosterone", 
                "intervention_name": "Testosterone", 
                "intervention_type": "Drug", 
                "other_name": "AndroFeme 1(testosterone 1% w/v cream)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Testosterone", 
                "Testosterone enanthate", 
                "Testosterone undecanoate", 
                "Testosterone 17 beta-cypionate", 
                "Methyltestosterone", 
                "Antidepressive Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Depression", 
            "Major Depressive Disorder (MDD)"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "avgerweck@partners.org", 
                    "last_name": "Anu Gerweck, NP", 
                    "phone": "617-724-1837"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Karen Miller, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Maurizio Fava, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Linda_Carpenter_MD@Brown.edu", 
                    "last_name": "Linda Carpenter, MD", 
                    "phone": "401-455-6349"
                }, 
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02906"
                    }, 
                    "name": "Butler Hospital"
                }, 
                "investigator": {
                    "last_name": "Linda Carpenter, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Collaborative Study: Testosterone Antidepressant Augmentation in Women", 
        "overall_contact": {
            "email": "avgerweck@partners.org", 
            "last_name": "Anu V Gerweck, NP", 
            "phone": "617-724-1837"
        }, 
        "overall_contact_backup": {
            "email": "adriccio@partners.org", 
            "last_name": "Ariana D Riccio, BS", 
            "phone": "617-726-2764"
        }, 
        "overall_official": [
            {
                "affiliation": "Massachusetts General Hospital", 
                "last_name": "Karen Miller, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Massachusetts General Hospital", 
                "last_name": "Maurizio Fava, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Butler Hospital", 
                "last_name": "Linda L Carpenter, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United States: Data Safety Monitoring Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Depressive symptoms", 
            "safety_issue": "No", 
            "time_frame": "Baseline, Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783574"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Karen Klahr Miller, MD", 
            "investigator_title": "Associate Professor of Medicine, Harvard Medical School", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Fatigue", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 8"
            }, 
            {
                "measure": "Sexual dysfunction", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Week 8"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institutes of Health (NIH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Lawley Pharmaceuticals", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}